TAMPA, Fla. and ALBANY, N.Y., June 22,
2016 /PRNewswire/ -- Teewinot Life Sciences
Corporation (Teewinot) and Albany Molecular Research, Inc. (NASDAQ:
AMRI) today announced that AMRI has licensed Teewinot's technology
to produce and sell the first commercially available
cannabichromene acid (CBCA) analytical standard. The CBCA
analytical standard is manufactured using Teewinot's patented
biosynthetic processes. Teewinot's proprietary processes involve
the expression of cannabinoid biosynthetic genes in microorganisms
for efficient production of large quantities of
cannabinoids.
"Interest in capturing the therapeutic value of cannabinoids is
on the upswing for basic research as well as for pharmaceutical
development," said William Marth,
president and CEO of AMRI. "As such, companies will need tools that
help them ensure their development programs meet the rigorous
requirements for drug development. AMRI is continually evaluating
and developing technologies for practical production of new, or
difficult to synthesize molecules to enhance efficiency and/or
quality."
Cannabinoids have therapeutic potential in a number of areas
including oncology, pain relief and inflammation, yet until
recently, few companies have pursued their study as therapeutic
agents. Efforts to advance cannabinoid compounds into therapeutic
development will require rigorous testing for quality, safety and
efficacy. This unique analytical standard is one tool that can
facilitate research, development, and quality control for
pharmaceutical applications of cannabinoids.
"We opted to work with AMRI to scale up the production of our
CBCA standard because the company has a global footprint and an
exceptional reputation within the field of bioprocess development,"
said Richard Peet, Teewinot's
executive vice president. "Partnering with a leader like AMRI will
ensure that the standards available using our biosynthetic platform
are consistent and results achieved with them are
reproducible."
About Teewinot Life Sciences Corporation
Teewinot Life
Sciences Corporation is an international biopharmaceutical company
focused on the use of synthetic biology and advanced formulation
for the production and implementation of cannabinoid based
therapies. With headquarters in Tampa, Florida, Teewinot manufactures and
licenses technology to make cost effective, pharmaceutically pure
cannabinoids as an industry leader in support of advancing medical
research and product development. Teewinot's global
technology and intellectual property represent a breakthrough in
the creation and delivery of cannabinoid based medicines. For
more information, please follow us on Twitter (@teewinot_corp) or
visit www.tlscorp.com.
About AMRI
Albany Molecular Research Inc. (AMRI) is a
global contract research and manufacturing organization that has
been working with the Life Sciences industry to improve patient
outcomes and the quality of life for more than two decades. With
locations in North America,
Europe and Asia, our key business segments include
Discovery and Development Services (DDS), Active Pharmaceutical
Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS
segment provides comprehensive services from hit identification to
IND, including expertise with diverse chemistry, library design and
synthesis, in vitro biology and pharmacology, drug metabolism and
pharmacokinetics, as well as natural products. API supports the
chemical development and cGMP manufacture of complex API, including
potent and cytotoxic compounds, controlled substances, steroids,
hormones, and sterile API. DPM supports development through
commercial scale production of complex liquid-filled and
lyophilized parenterals, sterile suspensions and ophthalmic
formulations. For more information about AMRI, please visit our
website at www.amriglobal.com or follow us on Twitter
(@amriglobal).
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/teewinot-life-sciences-corporation-licenses-biosynthetic-technology-to-amri-for-the-production-and-sale-of-the-first-commercially-available-cbca-analytical-standard-300288249.html
SOURCE AMRI